PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26101070-10 2015 HIF-1alpha, VEGF, SDF-1alpha, TGF-beta1, IL-10 mRNA and their protein levels were significantly higher on days 3, 7 and 14 in deferoxamine-treated rats. Deferoxamine 126-138 vascular endothelial growth factor A Rattus norvegicus 12-16 33029500-8 2020 For comparison, alendronate combined with DFO further improved the bone volume, trabecular number, trabecular separation, and trabecular thickness with lower ratio of osteocyte lacunae and OC number, higher expression of OCN and VEGF and upregulated signal factors of HIF-1alpha and beta-catenin, and decreased RANKL and NFATc1. Deferoxamine 42-45 vascular endothelial growth factor A Rattus norvegicus 229-233 32590679-0 2020 Recipient-Site Preconditioning with Deferoxamine Increases Fat Graft Survival by Inducing VEGF and Neovascularization in a Rat Model. Deferoxamine 36-48 vascular endothelial growth factor A Rattus norvegicus 90-94 32590680-0 2020 Reply: Recipient-Site Preconditioning with Deferoxamine Increases Fat Graft Survival by Inducing VEGF and Neovascularization in a Rat Model. Deferoxamine 43-55 vascular endothelial growth factor A Rattus norvegicus 97-101 32590681-0 2020 Recipient-Site Preconditioning with Deferoxamine Increases Fat Graft Survival by Inducing VEGF and Neovascularization in a Rat Model. Deferoxamine 36-48 vascular endothelial growth factor A Rattus norvegicus 90-94 32590682-0 2020 Reply: Recipient-Site Preconditioning with Deferoxamine Increases Fat Graft Survival by Inducing VEGF and Neovascularization in a Rat Model. Deferoxamine 43-55 vascular endothelial growth factor A Rattus norvegicus 97-101 31568298-0 2019 Recipient-Site Preconditioning with Deferoxamine Increases Fat Graft Survival by Inducing VEGF and Neovascularization in a Rat Model. Deferoxamine 36-48 vascular endothelial growth factor A Rattus norvegicus 90-94 31568299-0 2019 Discussion: Recipient-Site Preconditioning with Deferoxamine Increases Fat-Graft Survival by Inducing VEGF and Neovascularization in a Rat Model. Deferoxamine 48-60 vascular endothelial growth factor A Rattus norvegicus 102-106 32383023-3 2020 Using an SCI model of moderate compression, rats were intraperitoneally injected with 30 mg/kg or 100 mg/kg DFO for 1-2 weeks, and significant neovascularization was found in the injured spinal cord, showing overexpression of hypoxia inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF), and an increase in the number of new blood vessels. Deferoxamine 108-111 vascular endothelial growth factor A Rattus norvegicus 275-309 32383023-3 2020 Using an SCI model of moderate compression, rats were intraperitoneally injected with 30 mg/kg or 100 mg/kg DFO for 1-2 weeks, and significant neovascularization was found in the injured spinal cord, showing overexpression of hypoxia inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF), and an increase in the number of new blood vessels. Deferoxamine 108-111 vascular endothelial growth factor A Rattus norvegicus 311-315 31630885-0 2020 HIF-1alpha and VEGF Are Involved in Deferoxamine-Ameliorated Traumatic Brain Injury. Deferoxamine 36-48 vascular endothelial growth factor A Rattus norvegicus 15-19 31630885-2 2020 This study aimed to investigate the neuroprotective effect of DFX and its effect on hypoxia-inducible factor 1 alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in rats after traumatic brain injury (TBI). Deferoxamine 62-65 vascular endothelial growth factor A Rattus norvegicus 134-168 31630885-2 2020 This study aimed to investigate the neuroprotective effect of DFX and its effect on hypoxia-inducible factor 1 alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) in rats after traumatic brain injury (TBI). Deferoxamine 62-65 vascular endothelial growth factor A Rattus norvegicus 170-174 31630885-9 2020 RESULTS: DFX treatment upregulated the expression of HIF-1alpha and VEGF after TBI. Deferoxamine 9-12 vascular endothelial growth factor A Rattus norvegicus 68-72 31630885-13 2020 The protective effect of DFX may, at least in part, be through upregulating the expression of HIF-1alpha and its downstream target gene VEGF. Deferoxamine 25-28 vascular endothelial growth factor A Rattus norvegicus 136-140 25075254-7 2014 We found that the expression of HIF-1alpha, VEGF, and p-Erk1/2 was significantly upregulated and peaked at 4 h after HI in DFO treated group, with higher level and earlier peak time than control group. Deferoxamine 123-126 vascular endothelial growth factor A Rattus norvegicus 44-48 25075254-9 2014 Our findings suggest that DFO might up-regulate HIF-1alpha and its target gene VEGF through Erk1/2 MAPK pathway in the developing rat brain after HI. Deferoxamine 26-29 vascular endothelial growth factor A Rattus norvegicus 79-83 17767813-1 2008 OBJECTIVE: Deferoxamine, an iron chelator, is reported to induce hypoxia-inducible factor 1 (HIF-1) that leads to transcriptional activation of numerous genes including vascular endothelial growth factor (VEGF) that is known to increase blood-brain barrier (BBB) permeability. Deferoxamine 11-23 vascular endothelial growth factor A Rattus norvegicus 169-203 23726275-7 2013 Compared to the vehicle or VEGF treatment, DFO significantly increased neovascularization through up-regulation of HIF-1alpha and target genes including VEGF and stromal cell-derived factor-1alpha (SDF-1alpha). Deferoxamine 43-46 vascular endothelial growth factor A Rattus norvegicus 27-31 23726275-7 2013 Compared to the vehicle or VEGF treatment, DFO significantly increased neovascularization through up-regulation of HIF-1alpha and target genes including VEGF and stromal cell-derived factor-1alpha (SDF-1alpha). Deferoxamine 43-46 vascular endothelial growth factor A Rattus norvegicus 153-157 21294962-3 2011 We aimed to develop pharmacological strategies for VEGF overexpression in pancreatic islets using the iron chelator deferoxamine (DFO), thus avoiding obstacles or safety risks associated with gene therapy. Deferoxamine 131-134 vascular endothelial growth factor A Rattus norvegicus 52-56 21294962-7 2011 DFO induced transient VEGF overexpression over 3 days, whereas infection with ADE resulted in prolonged VEGF overexpression lasting 14 days; however, this was toxic and decreased islet viability and functionality. Deferoxamine 0-3 vascular endothelial growth factor A Rattus norvegicus 22-26 17767813-1 2008 OBJECTIVE: Deferoxamine, an iron chelator, is reported to induce hypoxia-inducible factor 1 (HIF-1) that leads to transcriptional activation of numerous genes including vascular endothelial growth factor (VEGF) that is known to increase blood-brain barrier (BBB) permeability. Deferoxamine 11-23 vascular endothelial growth factor A Rattus norvegicus 205-209 17767813-2 2008 This study was performed to test whether deferoxamine would disrupt BBB further in focal cerebral ischemia by altering the level of VEGF. Deferoxamine 41-53 vascular endothelial growth factor A Rattus norvegicus 132-136 17767813-10 2008 The number of areas that were stained with VEGF antibody in the deferoxamine 18 group (106 +/- 5/mm2) was significantly higher than that in the control group (54 +/- 2/mm2) or deferoxamine 48 group (58 +/- 1/mm2). Deferoxamine 64-76 vascular endothelial growth factor A Rattus norvegicus 43-47 17767813-11 2008 DISCUSSION: Our data suggest that deferoxamine induced an increase in VEGF but that its effect depends on the time of administration. Deferoxamine 34-46 vascular endothelial growth factor A Rattus norvegicus 70-74 17767813-12 2008 The increase in VEGF by deferoxamine could aggravate the disruption of BBB in focal cerebral ischemia. Deferoxamine 24-36 vascular endothelial growth factor A Rattus norvegicus 16-20 18374106-0 2008 Overexpression of vascular endothelial growth factor in vitro using deferoxamine: a new drug to increase islet vascularization during transplantation. Deferoxamine 68-80 vascular endothelial growth factor A Rattus norvegicus 18-52 18374106-2 2008 Deferoxamine (DFO), an iron chelator, increases vascular endothelial growth factor (VEGF) expression in cells. Deferoxamine 0-12 vascular endothelial growth factor A Rattus norvegicus 84-88 18374106-2 2008 Deferoxamine (DFO), an iron chelator, increases vascular endothelial growth factor (VEGF) expression in cells. Deferoxamine 14-17 vascular endothelial growth factor A Rattus norvegicus 48-82 18374106-2 2008 Deferoxamine (DFO), an iron chelator, increases vascular endothelial growth factor (VEGF) expression in cells. Deferoxamine 14-17 vascular endothelial growth factor A Rattus norvegicus 84-88 18374106-11 2008 RT-PCR analysis showed stimulation of VEGF mRNA in the presence of 10 micromol/L of DFO in islets at 3 days after culture. Deferoxamine 84-87 vascular endothelial growth factor A Rattus norvegicus 38-42 18374106-12 2008 Finally, 10 micromol/L of DFO stimulated secretion of VEGF 7.95 +/- 0.84 versus 1.80 +/- 1.10 pg/microg total protein with 10 micromol/L of DFO in rat islets at 3 days after culture, n = 3; P < .001). Deferoxamine 26-29 vascular endothelial growth factor A Rattus norvegicus 54-58 18374106-12 2008 Finally, 10 micromol/L of DFO stimulated secretion of VEGF 7.95 +/- 0.84 versus 1.80 +/- 1.10 pg/microg total protein with 10 micromol/L of DFO in rat islets at 3 days after culture, n = 3; P < .001). Deferoxamine 140-143 vascular endothelial growth factor A Rattus norvegicus 54-58 18374106-13 2008 The use of DFO to stimulate VEGF expression and increase islet vascularization may be a realistic approach to improve islet viability during transplantation. Deferoxamine 11-14 vascular endothelial growth factor A Rattus norvegicus 28-32 18374106-2 2008 Deferoxamine (DFO), an iron chelator, increases vascular endothelial growth factor (VEGF) expression in cells. Deferoxamine 0-12 vascular endothelial growth factor A Rattus norvegicus 48-82 34763682-12 2021 RESULTS: The results of PCR showed that the mRNA levels of VEGF and CD31 in the DFO group were significantly higher than those in the control group. Deferoxamine 80-83 vascular endothelial growth factor A Rattus norvegicus 59-63 12376368-3 2002 Upregulation of VEGF mRNA by hypoxia was mimicked by CoCl2 and desferrioxamine in normoxic AEC and was not prevented by inhibitors of reactive oxygen species, suggesting that hypoxic VEGF regulation involved an O2-dependent protein that requires ferrous ions but is independent of reactive oxygen species generation. Deferoxamine 63-78 vascular endothelial growth factor A Rattus norvegicus 16-20 7558244-6 1995 Treatment of astrocytes with CoCl2 or desferrioxamine results in a similar induction of VEGF, suggesting that the oxygen sensor regulating VEGF expression in astrocytes is a heme-containing molecule. Deferoxamine 38-53 vascular endothelial growth factor A Rattus norvegicus 88-92 7558244-6 1995 Treatment of astrocytes with CoCl2 or desferrioxamine results in a similar induction of VEGF, suggesting that the oxygen sensor regulating VEGF expression in astrocytes is a heme-containing molecule. Deferoxamine 38-53 vascular endothelial growth factor A Rattus norvegicus 139-143 34763682-13 2021 The immunohistochemistry results indicated that positive cell expression of HIF-1a, VEGF, and CD31 in the DFO group was also higher. Deferoxamine 106-109 vascular endothelial growth factor A Rattus norvegicus 84-88